

# Fabio Salvatore Macaluso

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11287249/publications.pdf>

Version: 2024-02-01

25  
papers

1,128  
citations

623734

14  
h-index

580821

25  
g-index

25  
all docs

25  
docs citations

25  
times ranked

2384  
citing authors

#	ARTICLE	IF	CITATIONS
1	Hepatitis C Virus Infection Is Associated With Increased Cardiovascular Mortality: A Meta-Analysis of Observational Studies. <i>Gastroenterology</i> , 2016, 150, 145-155.e4.	1.3	201
2	The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2015, 62, 1101-1110.	7.3	183
3	Screening of colorectal cancer: present and future. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 1131-1146.	2.4	123
4	Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infection. <i>Liver International</i> , 2011, 31, 507-515.	3.9	70
5	Cardiovascular diseases and HCV infection: a simple association or more?. <i>Gut</i> , 2014, 63, 369-375.	12.1	67
6	Steatosis affects the performance of liver stiffness measurement for fibrosis assessment in patients with genotype 1 chronic hepatitis C. <i>Journal of Hepatology</i> , 2014, 61, 523-529.	3.7	67
7	Genetic background in nonalcoholic fatty liver disease: A comprehensive review. <i>World Journal of Gastroenterology</i> , 2015, 21, 11088.	3.3	66
8	Herbal hepatotoxicity: a hidden epidemic. <i>Internal and Emergency Medicine</i> , 2013, 8, 13-22.	2.0	61
9	COVID-19 in patients with inflammatory bowel disease: A systematic review of clinical data. <i>Digestive and Liver Disease</i> , 2020, 52, 1222-1227.	0.9	38
10	Industrial, not fruit fructose intake is associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients. <i>Journal of Hepatology</i> , 2013, 59, 1169-1176.	3.7	33
11	Effectiveness and safety of Ustekinumab for the treatment of Crohn's disease in real-life experiences: a meta-analysis of observational studies. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 193-203.	3.1	33
12	Anti-interleukin-12 and anti-interleukin-23 agents in Crohn's disease. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 89-98.	3.1	31
13	Serum $\gamma$ -glutamyl Transferase Levels, Insulin Resistance and Liver Fibrosis in Patients with Chronic Liver Diseases. <i>PLoS ONE</i> , 2012, 7, e51165.	2.5	29
14	Diagnostic and vaccine strategies to prevent infections in patients with inflammatory bowel disease. <i>Journal of Infection</i> , 2017, 74, 433-441.	3.3	28
15	Risk factors and timing for colectomy in chronically active refractory ulcerative colitis: A systematic review. <i>Digestive and Liver Disease</i> , 2019, 51, 613-620.	0.9	14
16	A propensity score weighted comparison of vedolizumab and adalimumab in Crohn's disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 105-111.	2.8	14
17	Body Mass Index and Liver Stiffness Affect Accuracy of Ultrasonography in Detecting Steatosis in Patients With Chronic Hepatitis C Virus Genotype 1 Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 878-884.e1.	4.4	13
18	Head-to-head comparison of biological drugs for inflammatory bowel disease: from randomized controlled trials to real-world experience. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110106.	3.2	13

#	ARTICLE	IF	CITATIONS
19	Vaccinations in patients with inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2021, 53, 1539-1545.	0.9	12
20	Severe Activity of Inflammatory Bowel Disease is a Risk Factor for Severe COVID-19. <i>Inflammatory Bowel Diseases</i> , 2023, 29, 217-221.	1.9	9
21	Effectiveness of Ustekinumab on Crohn's Disease Associated Spondyloarthritis: Real-World Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD). <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1381-1384.	3.1	8
22	Could Patients With Inflammatory Bowel Disease Treated With Immunomodulators or Biologics Be at Lower Risk for Severe Forms of COVID-19?. <i>Gastroenterology</i> , 2021, 160, 1877-1878.	1.3	6
23	JAK Inhibition as a Therapeutic Strategy for Inflammatory Bowel Disease. <i>Current Drug Metabolism</i> , 2020, 21, 247-255.	1.2	4
24	How clinicians and pathologists interact concerning inflammatory bowel disease in Italy: An IG-IBD survey. <i>Digestive and Liver Disease</i> , 2018, 50, 734-736.	0.9	3
25	Residual risk of hepatocellular carcinoma after HCV eradication: more than meets the eye. <i>Future Microbiology</i> , 2015, 10, 977-988.	2.0	2